Talk:LEADER trial

Discussion page·2 threads·no archives

This is the discussion page for the article LEADER trial. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.

Renal signal was a markerResolved

The renal composite in LEADER was driven by macroalbuminuria, which is a marker. Saying so prevents the trial being cited as renal outcome evidence. — eGFR_Esme (talk) 09:50, 25 February 2026 (UTC)

And it explains why a dedicated renal trial was needed afterwards. Cross-linked to FLOW trial. ✓ Done — FlowTrialFraser (talk) 13:25, 25 February 2026 (UTC)

Resolved. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

Enrichment and generalisationDone

Event enrichment buys power and costs generalisability. Both halves are stated, which is more than most summaries manage. — LeaderLoic (talk) 10:15, 19 May 2026 (UTC)

It is a general point about outcome trials and could be linked from several articles. ✓ Done — PreregPriya (talk) 13:50, 19 May 2026 (UTC)

Done. This thread is closed. Reopening it is fine if new sources appear; please add a new subsection rather than editing the closed discussion.

This page was last edited on 19 May 2026, by PreregPriya. Text is available under the PeptidePedia Wiki Content Licence (PPCL-BY-SA 4.0).